News Related to Catalent, Inc.

Related coverage linked through entity extraction aliases.

Large Molecule Drug Substance CDMO Market Projected to Grow 9% Annually Through 2031

Mar 05, 2026

The large molecule drug substance CDMO market is expected to grow at approximately 9% CAGR through 2031, driven by rising demand for biologics and biosimilars, streamlined regulatory approval pathways, and increasing FDA and EMA approvals for biologic therapies.

Scholar Rock Prepares Apitegromab BLA Resubmission Following FDA Facility Reinspection

Mar 04, 2026

Scholar Rock plans to resubmit its biologics license application for apitegromab in spinal muscular atrophy following FDA reinspection of the Catalent Indiana fill-finish facility, with a U.S. launch anticipated in 2026.